Share on LinkedInShare on LinkedIn

ARTICLE · 15 SEPTEMBER 2023

The Interplay: Key Decisions At The Intersection Of Antitrust & Life Sciences - September 2023

WilmerHale
WilmerHale
Contributor
WilmerHale

WilmerHale

WilmerHale's London office was established more than 40 years ago. With lawyers qualified in the...

View firm profile
Explore more from WilmerHale

This marks the first issue of WilmerHale's The Interplay: Key Decisions at the Intersection of Antitrust & Life Sciences, a monthly bulletin that will highlight developments in the antitrust and life sciences space.

United StatesAntitrust/Competition Law

This marks the first issue of WilmerHale's The Interplay: Key Decisions at the Intersection of Antitrust & Life Sciences, a monthly bulletin that will highlight developments in the antitrust and life sciences space. We will cover important decisions in the appellate courts, dispositive decisions from district courts and relevant updates and developments from the FTC. This will serve as a reliable and informative resource for readers who wish to stay current on this dynamic area of litigation. Beginning this month, you will receive digestible summaries of these decisions and other recent developments.

Federal Trade Commission v. Amgen, Inc. (N.D. Ill.) – FTC and State AGs End Challenge to Amgen/Horizon Deal. On September 1, the FTC announced it has agreed to a proposed consent order with Amgen, settling its suit to block Amgen's proposed acquisition of Horizon Therapeutics. In May 2023, the FTC and six state attorneys general alleged that the deal would enable

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from